Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901487 | 0.82 | RBP4 (0.61) | CYP4F2CYP4A11RBP4PTGER1 | |
| SCHEMBL12409225 | 0.80 | RBP4 (0.61) | RBP4PTGER1 | |
| SCHEMBL12409190 | 0.75 | RBP4 (0.52) | RBP4 | |
| SCHEMBL1898327 | 0.75 | RBP4 (0.64) | RBP4 | |
| SCHEMBL23434873 | 0.75 | IRAK4 (0.45) | CYP4F2CYP4A11RBP4PTGER1ENPP2 | |
| SCHEMBL12409207 | 0.74 | PTGDR2 (0.55) | RBP4PTGER1PTGDR2PTGDRSLC6A4 | |
| SCHEMBL18404602 | 0.73 | RBP4 (0.55) | RBP4PTGDR2PTGDRENPP2ATXN2 | |
| SCHEMBL12409141 | 0.73 | RBP4 (0.58) | RBP4PTGER1 | |
| SCHEMBL12409183 | 0.72 | RBP4 (0.52) | RBP4 | |
| SCHEMBL12409188 | 0.72 | RBP4 (0.52) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| WO-2009042444-A2 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, ALDH1A2 | CYP4F2 2094/4885CYP4A11 580/4885RBP4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.